MANILA, Philippines - Concerned about the alarming increase of diabetes incidence in the country, St. Luke’s Medical Center Global City’s (SLMC-GC) Diabetes Thyroid and Endocrine Center (DTEC) and Medtronic International partnered to help reduce the incidence of hypoglycemia, hyperglycemia, and DKA among patients with all types of diabetes.
Through a Memorandum of Agreement (MOA), SLMC-GC DTEC, Medtronic, and FMEI, Medtronic’s distributor in the Philippines, agree to help patients gain better knowledge and understanding in managing their diabetes, and through the breakthrough technology that the Medtronic insulin pump therapy and iPRO continuous glucose monitoring system offers, patients have better access to advanced and superior health care services that the center offers.
The SLMC-GC Diabetes, Thyroid and Endocrine Center specializes in disorders of the endocrine system including Diabetes Mellitus. Its well-trained endocrine specialists are available to diagnose and treat patients with common, as well as rare conditions in the endocrine glands. Through this partnership, the endocrine center has acquired the latest technology in the monitoring and treatment of diabetes. After the signing of the MOA, the endocrine center also opened the first insulin pump therapy unit in the Philippines which caters to patients who wish to be on the insulin pump or the CGMs. The acquisition of this modern technology is the first in the Philippines and will be available at the Endocrine Center of St Luke’s Medical Center.
Children, adults, and even pregnant women will now be able to enjoy freedom from having to go through daily injections and be able to pursue a more flexible lifestyle.